Sensei Biotherapeutics マネジメント
マネジメント 基準チェック /24
Sensei Biotherapeutics' CEO is John Celebi, appointed in Feb 2018, has a tenure of 6.75 years. total yearly compensation is $1.01M, comprised of 52.6% salary and 47.4% bonuses, including company stock and options. directly owns 0.25% of the company’s shares, worth $30.63K. The average tenure of the management team and the board of directors is 1.9 years and 3.8 years respectively.
主要情報
John Celebi
最高経営責任者
US$1.0m
報酬総額
| CEO給与比率 | 52.6% |
| CEO在任期間 | 6.8yrs |
| CEOの所有権 | 0.2% |
| 経営陣の平均在職期間 | 1.9yrs |
| 取締役会の平均在任期間 | 3.8yrs |
経営陣の近況
Recent updates
Is Sensei Biotherapeutics (NASDAQ:SNSE) In A Good Position To Deliver On Growth Plans?
Nov 03
We Think Sensei Biotherapeutics (NASDAQ:SNSE) Needs To Drive Business Growth Carefully
Jul 02Here's Why We're Watching Sensei Biotherapeutics' (NASDAQ:SNSE) Cash Burn Situation
Mar 14We're Hopeful That Sensei Biotherapeutics (NASDAQ:SNSE) Will Use Its Cash Wisely
Aug 14Sensei Biotherapeutics GAAP EPS of -$0.34 beats by $0.06
Aug 09Here's Why We're Watching Sensei Biotherapeutics' (NASDAQ:SNSE) Cash Burn Situation
Apr 18Sensei Biotherapeutics (NASDAQ:SNSE) Is In A Good Position To Deliver On Growth Plans
Nov 16CEO報酬分析
| 日付 | 総報酬 | 給与 | 会社業績 |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$30m |
| Mar 31 2024 | n/a | n/a | -US$32m |
| Dec 31 2023 | US$1m | US$532k | -US$34m |
| Sep 30 2023 | n/a | n/a | -US$39m |
| Jun 30 2023 | n/a | n/a | -US$45m |
| Mar 31 2023 | n/a | n/a | -US$46m |
| Dec 31 2022 | US$2m | US$513k | -US$49m |
| Sep 30 2022 | n/a | n/a | -US$46m |
| Jun 30 2022 | n/a | n/a | -US$42m |
| Mar 31 2022 | n/a | n/a | -US$41m |
| Dec 31 2021 | US$7m | US$487k | -US$37m |
| Sep 30 2021 | n/a | n/a | -US$33m |
| Jun 30 2021 | n/a | n/a | -US$28m |
| Mar 31 2021 | n/a | n/a | -US$23m |
| Dec 31 2020 | US$2m | US$395k | -US$20m |
報酬と市場: John's total compensation ($USD1.01M) is above average for companies of similar size in the US market ($USD655.65K).
報酬と収益: John's compensation has been consistent with company performance over the past year.
CEO（最高経営責任者
John Celebi (52 yo)
6.8yrs
在職期間
US$1,012,289
報酬
Mr. John K. Celebi, MBA serves as President, Chief Executive Officer and Director of Alvaxa Biosciences, Incorporated since February 2018. Mr. Celebi serves as President and Chief Executive Officer of Sens...
リーダーシップ・チーム
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| President | 6.8yrs | US$1.01m | 0.25% $ 30.6k | |
| Chief Scientific Officer | 1.9yrs | US$739.08k | 0.14% $ 17.4k | |
| Senior VP of Finance | less than a year | データなし | データなし | |
| Vice President of Investor Relations & Communications | no data | データなし | データなし | |
| Senior VP | 2.3yrs | データなし | データなし | |
| Chief Business Officer | less than a year | データなし | データなし | |
| Chief Medical Officer | no data | データなし | データなし |
1.9yrs
平均在職期間
50yo
平均年齢
経験豊富な経営陣: SNSE's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.
取締役
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| President | 6.8yrs | US$1.01m | 0.25% $ 30.6k | |
| Independent Director | 8.9yrs | US$75.56k | 1.35% $ 166.3k | |
| Independent Chairman | 2.7yrs | US$101.57k | 0.063% $ 7.8k | |
| Independent Director | 7.8yrs | US$73.39k | 0.084% $ 10.4k | |
| Member of Immuno-Oncology Advisory Board | 3.5yrs | データなし | データなし | |
| Independent Director | 3.8yrs | US$69.32k | 0.018% $ 2.2k | |
| Independent Director | 4.8yrs | US$68.43k | データなし | |
| Member of Immuno-Oncology Advisory Board | no data | データなし | データなし | |
| Member of Immuno-Oncology Advisory Board | 3.5yrs | データなし | データなし | |
| Independent Director | 3.3yrs | US$62.24k | 0.018% $ 2.2k | |
| Member of Immuno-Oncology Advisory Board | no data | データなし | データなし | |
| Member of Immuno-Oncology Advisory Board | no data | データなし | データなし |
3.8yrs
平均在職期間
60yo
平均年齢
経験豊富なボード: SNSE's board of directors are considered experienced (3.8 years average tenure).